Innorex Pharmaceuticals

Innorex Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule inhibitors for autoimmune and inflammatory diseases. The company specializes in the design of highly selective kinase inhibitors, particularly targeting the Janus kinase (JAK) pathway to minimize the off-target side effects associated with earlier-generation pan-JAK inhibitors. Its lead clinical candidate, INN-101, is a selective JAK1 inhibitor being evaluated for efficacy in dermatological conditions such as atopic dermatitis. By leveraging a proprietary medicinal chemistry approach, Innorex aims to provide oral therapies that offer improved safety and potency profiles for chronic immunological disorders. The company maintains a growing pipeline of candidates addressing unmet needs in rheumatology and dermatology.